The abstract says financial risks have contributed to a lack of progress in developing curative glioblastoma treatments. It describes a portfolio-based strategy for parallel discovery as a way to reduce risks in potentially transformative clinical trials.
Alpheus Medical raised $16 million in Series A financing to support a first-in-human trial of its non-invasive sonodynamic drug-device therapy for recurrent high-grade gliomas. The company is developing a sonodynamic therapy platform targeting solid body cancers.
DelMar Pharmaceuticals received a $500,000 loan from the National Brain Tumor Society and the National Foundation for Cancer Research to support preparation of VAL-083 for participation in a program.
Alpheus Medical is enrolling patients in a multicenter Phase 1 clinical trial for recurrent glioblastoma. The FDA granted the company Orphan Drug status, according to the announcement.
The page provides contact information for the Brain Tumor Investment fund and says prospective applicants can email non-confidential materials for consideration in a future BTIF investment.
The Brain Tumor Investment Fund is a venture philanthropy fund that draws on the National Brain Tumor Society’s 30 years of experience and invests in biotechnology, pharmaceutical, and medical device companies developing products to improve lives.
